12,218 results on '"Natalizumab"'
Search Results
2. A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS)
3. Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS (DELIVER-MS)
4. Natalizumab in Recurrent, Refractory or Progressive Pulmonary Metastatic Osteosarcoma
5. TOPIK Study: A Study to Report Progressive Multifocal Leukoencephalopathy and Other Serious Opportunistic Infections in Natalizumab Treated Participants
6. Best Available Therapy Versus Autologous Hematopoetic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS) (BEAT-MS)
7. A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple Sclerosis
8. Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)
9. A Study to Investigate the Radiological Onset of Action After Treatment Initiation With Subcutaneous (SC) Natalizumab in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
10. Natalizumab Subcutaneous Immunogenicity and Safety Study (SIMPLIFY)
11. CD INFORM: Investigating Natalizumab Through Further Observational Research and Monitoring (INFORM)
12. A Proof-of-Concept Study to Correlate Retinal Nerve Fiber Layer Changes in Patients With Multiple Sclerosis Treated With Natalizumab or Interferon Beta 1-a (PRTOECT)
13. Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD)
14. A Study for Tysabri Participant Preference
15. A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration
16. Natalizumab and Chronic Inflammation
17. Tysabri Observational Program (TOP)
18. Comparing the Safety and Benefit of Natalizumab (Tysabri®) At-home Infusion vs At-hospital Infusion in Multiple Sclerosis (Tys at Home)
19. Tysabri Observational Cohort Study - Multiple Sclerosis (MS) Registries
20. Inflammatory Response In Schizophrenia (IRIS)
21. Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial (TREAT-MS)
22. Natalizumab in Preventing Post-partum Relapses in Multiple Sclerosis (NAPPREMS)
23. Examining Effects of Tysabri on Cognitive Fatigue Using fMRI
24. Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants (TYPIFI)
25. Diffuse white matter pathology in multiple sclerosis during treatment with dimethyl fumarate—An observational study of changes in normal-appearing white matter using proton magnetic resonance spectroscopy.
26. Neuroaxonal damage in natalizumab-treated MS patients: The role of JCV antibody titres.
27. Serum Vitamin D3 as a Potential Biomarker for Neuronal Damage in Smoldering Multiple Sclerosis.
28. Pediatric-onset Multiple Sclerosis treatment: a multicentre observational study comparing natalizumab with fingolimod.
29. 56th National Congress of the Italian Society of Clinical Biochemistry and Clinical Molecular Biology (SIBioC – Laboratory Medicine).
30. Patient Preference for Subcutaneous Versus Intravenous Administration with Every-6-Week Natalizumab (Tysabri®) Dosing: NOVA Phase IIIb Extension Study (Part 2).
31. Enhanced and cross-reactive in vitro memory B cell response against Epstein-Barr virus nuclear antigen 1 in multiple sclerosis.
32. Altered lymphocyte profiles and herpes zoster infections in patients with multiple sclerosis on natalizumab.
33. A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic.
34. T cell activation markers CD38 and HLA-DR indicative of non-seroconversion in anti-CD20-treated patients with multiple sclerosis following SARS-CoV-2 mRNA vaccination.
35. Evaluation of ovarian reserve and the assisted reproductive technology (ART) cycles' outcome as well as the relapse rate within one year after ART in women with multiple sclerosis: a case-control study.
36. Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis.
37. Ocrelizumab use in multiple sclerosis: a real-world experience in a changing therapeutic scenario.
38. A comparison of natalizumab and ocrelizumab on disease progression in multiple sclerosis.
39. Old and New Strategies in the Treatment of Pediatric Multiple Sclerosis: A Personal View for a New Treatment Approach.
40. Natalizumab in Multiple Sclerosis: A Single Centre Real-World Study.
41. Old and New Biologics and Small Molecules in Inflammatory Bowel Disease: Anti Integrins
42. Patient Preference for Subcutaneous Versus Intravenous Administration with Every-6-Week Natalizumab (Tysabri®) Dosing: NOVA Phase IIIb Extension Study (Part 2)
43. Insight into motor fatigue mechanisms in natalizumab treated multiple sclerosis patients with wearing off
44. COVID-19 Infection in Multiple Sclerosis Patients Treated with Rituximab Compared to Natalizumab and Healthy Controls: A Real-World Multicenter Study
45. Progressive multifocal leukoencephalopathy in the clinical practice of a neurologist. Case report
46. Long-lasting severe anemia following treatment with natalizumab for relapsing–remitting multiple sclerosis: a case report
47. Frequent detection of IFN-gamma-producing memory effector and effector T cells in patients with progressive multifocal leukoencephalopathy.
48. Hyper-reflective foci changes in RRMS under natalizumab therapy.
49. Implications of disease-modifying therapies for multiple sclerosis on immune cells and response to COVID-19 vaccination.
50. Overcoming Vemurafenib Resistance in Metastatic Melanoma: Targeting Integrins to Improve Treatment Efficacy.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.